In a concerning revelation, internal records have uncovered meetings between top officials from the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson, where they discussed strategic legal moves regarding the company’s controversial glyphosate herbicides. These discussions took place just before the Trump administration took significant steps to bolster Bayer’s position in ongoing litigation, raising alarms about corporate influence over regulatory practices in the United States.
A Meeting of Concern
On 17 June 2025, Anderson, along with other senior Bayer executives, met with key EPA officials, including Lee Zeldin, the agency’s administrator. This meeting was ostensibly about “litigation issues,” specifically focusing on the potential for Supreme Court intervention concerning glyphosate, a herbicide linked to cancer allegations from thousands of American users.
The backdrop of this meeting is troubling. Bayer has been grappling with numerous lawsuits claiming that its glyphosate products, particularly Roundup, are responsible for causing cancer. The core of these allegations hinges on claims that Bayer failed to adequately warn consumers about the associated risks, a position substantiated by various research studies over the years.
Bayer’s legal strategy to mitigate these claims involves arguing that if the EPA does not mandate a cancer warning on glyphosate products, the company should not be held liable for omitting such warnings. While one appellate court has sided with Bayer, other courts have rejected this argument, including the Biden administration’s solicitor general, who has expressed opposition to Bayer’s position.
Regulatory Support for Bayer
Following the EPA meeting, the Trump administration’s support for Bayer intensified. In a pivotal move, the administration filed a brief with the Supreme Court encouraging the justices to hear Bayer’s case, a request that was subsequently granted, with hearings set for 27 April. Furthermore, the White House invoked the Defense Production Act to safeguard glyphosate production and shield Bayer from liability, actions that have alarmed environmental advocates.
In a statement, Bayer characterised the meeting as a standard part of the regulatory process, asserting its transparency regarding glyphosate litigation. However, critics argue that the reality is more sinister. Nathan Donley, environmental health science director at the Center for Biological Diversity, emphasised that the meeting exemplifies the overwhelming power that corporations wield over regulatory decisions that could impact public health.
Disparities in Access
The implications of this meeting extend beyond the realm of legal strategy; they illuminate a stark disparity in access to decision-makers. Critics like Whitney Di Bona, an attorney and consumer safety advocate, highlighted the troubling notion that the CEO of a major pesticide company can engage directly with the EPA while the voices of cancer victims and their families remain unheard. This raises essential questions about the fairness of regulatory processes and who gets to influence them.
Naomi Oreskes, a Harvard professor, noted that the meeting reflects a larger trend where industry leaders have privileged access to government officials, overshadowing the voices of ordinary citizens. The lack of equal opportunity for public engagement in regulatory matters is deeply troubling, particularly when such high-stakes health issues are at play.
A Call for Accountability
Advocates for environmental health, like Zen Honeycutt, founder of Moms Across America, have voiced their frustrations at the apparent coercion exerted by chemical companies on regulatory bodies. Despite efforts to engage with EPA leadership, their calls for restrictions or bans on harmful pesticides have often been ignored, leaving communities vulnerable to the risks associated with these products.
The concerning dynamics surrounding Bayer’s relationship with the Trump administration highlight the urgent need for reforms that prioritise public health over corporate profits. As discussions continue around the future of glyphosate in the US, the calls for accountability and transparency in regulatory processes must become a focal point for activists and concerned citizens alike.
Why it Matters
This unfolding story underscores a critical issue: the intersection of corporate power and public health policy. As the Trump administration’s actions suggest a prioritisation of corporate interests over community safety, it becomes imperative for citizens to demand greater transparency and accountability from regulatory bodies. The influence of companies like Bayer signals a pressing need for reform in how environmental regulations are shaped, ensuring that the health and safety of the public are not sacrificed at the altar of profit. The stakes are high, and the fight for justice for those affected by glyphosate is far from over.
